nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—SLK—seminal vesicle—rectum cancer	0.00187	0.0037	CbGeAlD
Crizotinib—EPHB4—seminal vesicle—rectum cancer	0.00186	0.00367	CbGeAlD
Crizotinib—PTK2B—smooth muscle tissue—rectum cancer	0.00185	0.00367	CbGeAlD
Crizotinib—LIMK2—mammalian vulva—rectum cancer	0.00185	0.00367	CbGeAlD
Crizotinib—ALK—female reproductive system—rectum cancer	0.00185	0.00365	CbGeAlD
Crizotinib—FER—female reproductive system—rectum cancer	0.00185	0.00365	CbGeAlD
Crizotinib—TYRO3—female reproductive system—rectum cancer	0.00185	0.00365	CbGeAlD
Crizotinib—NUAK2—mammalian vulva—rectum cancer	0.00185	0.00365	CbGeAlD
Crizotinib—JAK2—seminal vesicle—rectum cancer	0.00184	0.00365	CbGeAlD
Crizotinib—MAP3K12—mammalian vulva—rectum cancer	0.00183	0.00363	CbGeAlD
Crizotinib—ACVR1—mammalian vulva—rectum cancer	0.00183	0.00363	CbGeAlD
Crizotinib—EPHA2—seminal vesicle—rectum cancer	0.00182	0.0036	CbGeAlD
Crizotinib—MAP3K19—female reproductive system—rectum cancer	0.00181	0.00358	CbGeAlD
Crizotinib—BMPR1B—female reproductive system—rectum cancer	0.00181	0.00358	CbGeAlD
Crizotinib—DCLK1—vagina—rectum cancer	0.00179	0.00354	CbGeAlD
Crizotinib—PTK2B—renal system—rectum cancer	0.00178	0.00353	CbGeAlD
Crizotinib—MAP3K3—seminal vesicle—rectum cancer	0.00178	0.00352	CbGeAlD
Crizotinib—MAP4K5—seminal vesicle—rectum cancer	0.00178	0.00352	CbGeAlD
Crizotinib—TNK2—female reproductive system—rectum cancer	0.00177	0.00351	CbGeAlD
Crizotinib—IGF1R—female reproductive system—rectum cancer	0.00177	0.00351	CbGeAlD
Crizotinib—PTK2—epithelium—rectum cancer	0.00177	0.00351	CbGeAlD
Crizotinib—MAP4K2—female reproductive system—rectum cancer	0.00175	0.00346	CbGeAlD
Crizotinib—NEK9—lymph node—rectum cancer	0.00174	0.00345	CbGeAlD
Crizotinib—RIPK2—urethra—rectum cancer	0.00174	0.00344	CbGeAlD
Crizotinib—STK3—female reproductive system—rectum cancer	0.00172	0.00341	CbGeAlD
Crizotinib—TIE1—female reproductive system—rectum cancer	0.00172	0.00341	CbGeAlD
Crizotinib—PTK2—smooth muscle tissue—rectum cancer	0.00171	0.00338	CbGeAlD
Crizotinib—RPS6KB1—epithelium—rectum cancer	0.0017	0.00337	CbGeAlD
Crizotinib—EPHB6—seminal vesicle—rectum cancer	0.0017	0.00336	CbGeAlD
Crizotinib—TYK2—smooth muscle tissue—rectum cancer	0.0017	0.00336	CbGeAlD
Crizotinib—AURKA—female reproductive system—rectum cancer	0.00168	0.00333	CbGeAlD
Crizotinib—EPHA4—urethra—rectum cancer	0.00168	0.00333	CbGeAlD
Crizotinib—IRAK1—smooth muscle tissue—rectum cancer	0.00167	0.00331	CbGeAlD
Crizotinib—EPHA5—vagina—rectum cancer	0.00167	0.0033	CbGeAlD
Crizotinib—FER—vagina—rectum cancer	0.00167	0.0033	CbGeAlD
Crizotinib—TESK1—female reproductive system—rectum cancer	0.00167	0.0033	CbGeAlD
Crizotinib—TNK1—vagina—rectum cancer	0.00165	0.00327	CbGeAlD
Crizotinib—PTK2—renal system—rectum cancer	0.00164	0.00325	CbGeAlD
Crizotinib—TBK1—renal system—rectum cancer	0.00164	0.00325	CbGeAlD
Crizotinib—RPS6KB1—smooth muscle tissue—rectum cancer	0.00164	0.00325	CbGeAlD
Crizotinib—YES1—seminal vesicle—rectum cancer	0.00164	0.00325	CbGeAlD
Crizotinib—MAP4K1—vagina—rectum cancer	0.00164	0.00324	CbGeAlD
Crizotinib—TYK2—renal system—rectum cancer	0.00163	0.00323	CbGeAlD
Crizotinib—AXL—smooth muscle tissue—rectum cancer	0.00163	0.00322	CbGeAlD
Crizotinib—TAOK3—seminal vesicle—rectum cancer	0.00162	0.00321	CbGeAlD
Crizotinib—PTK2—urethra—rectum cancer	0.00161	0.00319	CbGeAlD
Crizotinib—TBK1—urethra—rectum cancer	0.00161	0.00319	CbGeAlD
Crizotinib—EPHB4—epithelium—rectum cancer	0.00161	0.00319	CbGeAlD
Crizotinib—IGF1R—vagina—rectum cancer	0.0016	0.00317	CbGeAlD
Crizotinib—TYK2—urethra—rectum cancer	0.0016	0.00317	CbGeAlD
Crizotinib—JAK2—epithelium—rectum cancer	0.0016	0.00317	CbGeAlD
Crizotinib—EPHA4—mammalian vulva—rectum cancer	0.0016	0.00317	CbGeAlD
Crizotinib—PRKD1—lymph node—rectum cancer	0.00159	0.00314	CbGeAlD
Crizotinib—LIMK2—female reproductive system—rectum cancer	0.00159	0.00314	CbGeAlD
Crizotinib—EPHA2—epithelium—rectum cancer	0.00158	0.00313	CbGeAlD
Crizotinib—MAP4K2—vagina—rectum cancer	0.00158	0.00313	CbGeAlD
Crizotinib—RPS6KB1—renal system—rectum cancer	0.00158	0.00313	CbGeAlD
Crizotinib—MAP3K12—female reproductive system—rectum cancer	0.00157	0.00311	CbGeAlD
Crizotinib—FLT3—female reproductive system—rectum cancer	0.00157	0.00311	CbGeAlD
Crizotinib—ACVR1—female reproductive system—rectum cancer	0.00157	0.00311	CbGeAlD
Crizotinib—LIMK1—lymph node—rectum cancer	0.00157	0.0031	CbGeAlD
Crizotinib—STK3—vagina—rectum cancer	0.00156	0.00309	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—rectum cancer	0.00155	0.00307	CbGeAlD
Crizotinib—RPS6KB1—urethra—rectum cancer	0.00155	0.00307	CbGeAlD
Crizotinib—LCK—urethra—rectum cancer	0.00154	0.00305	CbGeAlD
Crizotinib—FGR—urethra—rectum cancer	0.00154	0.00305	CbGeAlD
Crizotinib—TEK—epithelium—rectum cancer	0.00154	0.00305	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—rectum cancer	0.00154	0.00305	CbGeAlD
Crizotinib—STK35—female reproductive system—rectum cancer	0.00154	0.00304	CbGeAlD
Crizotinib—AXL—urethra—rectum cancer	0.00154	0.00304	CbGeAlD
Crizotinib—TBK1—mammalian vulva—rectum cancer	0.00154	0.00304	CbGeAlD
Crizotinib—TYK2—mammalian vulva—rectum cancer	0.00153	0.00302	CbGeAlD
Crizotinib—PRKD3—lymph node—rectum cancer	0.00153	0.00302	CbGeAlD
Crizotinib—AURKA—vagina—rectum cancer	0.00152	0.00301	CbGeAlD
Crizotinib—TESK1—vagina—rectum cancer	0.00151	0.00298	CbGeAlD
Crizotinib—IRAK1—mammalian vulva—rectum cancer	0.00151	0.00298	CbGeAlD
Crizotinib—EPHB4—renal system—rectum cancer	0.0015	0.00296	CbGeAlD
Crizotinib—DSTYK—lymph node—rectum cancer	0.00149	0.00295	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—rectum cancer	0.00149	0.00294	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—rectum cancer	0.00149	0.00294	CbGeAlD
Crizotinib—JAK2—renal system—rectum cancer	0.00148	0.00294	CbGeAlD
Crizotinib—BMP2K—female reproductive system—rectum cancer	0.00148	0.00293	CbGeAlD
Crizotinib—SLK—urethra—rectum cancer	0.00148	0.00293	CbGeAlD
Crizotinib—RPS6KB1—mammalian vulva—rectum cancer	0.00148	0.00293	CbGeAlD
Crizotinib—BLK—lymph node—rectum cancer	0.00147	0.00291	CbGeAlD
Crizotinib—FGR—mammalian vulva—rectum cancer	0.00147	0.00291	CbGeAlD
Crizotinib—LCK—mammalian vulva—rectum cancer	0.00147	0.00291	CbGeAlD
Crizotinib—EPHB4—urethra—rectum cancer	0.00147	0.00291	CbGeAlD
Crizotinib—MERTK—vagina—rectum cancer	0.00147	0.0029	CbGeAlD
Crizotinib—AXL—mammalian vulva—rectum cancer	0.00146	0.0029	CbGeAlD
Crizotinib—JAK2—urethra—rectum cancer	0.00146	0.00289	CbGeAlD
Crizotinib—LTK—lymph node—rectum cancer	0.00146	0.00288	CbGeAlD
Crizotinib—CASK—lymph node—rectum cancer	0.00146	0.00288	CbGeAlD
Crizotinib—EPHA2—urethra—rectum cancer	0.00144	0.00285	CbGeAlD
Crizotinib—LIMK2—vagina—rectum cancer	0.00143	0.00284	CbGeAlD
Crizotinib—TEK—renal system—rectum cancer	0.00143	0.00283	CbGeAlD
Crizotinib—NUAK2—vagina—rectum cancer	0.00143	0.00283	CbGeAlD
Crizotinib—PTK2B—female reproductive system—rectum cancer	0.00143	0.00283	CbGeAlD
Crizotinib—ACVR1—vagina—rectum cancer	0.00142	0.00281	CbGeAlD
Crizotinib—MAP3K12—vagina—rectum cancer	0.00142	0.00281	CbGeAlD
Crizotinib—RIPK2—female reproductive system—rectum cancer	0.00142	0.00281	CbGeAlD
Crizotinib—CSF1R—seminal vesicle—rectum cancer	0.00142	0.0028	CbGeAlD
Crizotinib—MAPK7—lymph node—rectum cancer	0.00141	0.00279	CbGeAlD
Crizotinib—TXK—lymph node—rectum cancer	0.00141	0.00279	CbGeAlD
Crizotinib—SLK—mammalian vulva—rectum cancer	0.00141	0.00279	CbGeAlD
Crizotinib—TEK—urethra—rectum cancer	0.00141	0.00278	CbGeAlD
Crizotinib—MAP3K3—urethra—rectum cancer	0.00141	0.00278	CbGeAlD
Crizotinib—MAP4K5—urethra—rectum cancer	0.00141	0.00278	CbGeAlD
Crizotinib—EPHB4—mammalian vulva—rectum cancer	0.0014	0.00277	CbGeAlD
Crizotinib—FES—lymph node—rectum cancer	0.0014	0.00276	CbGeAlD
Crizotinib—STK35—vagina—rectum cancer	0.00139	0.00275	CbGeAlD
Crizotinib—JAK2—mammalian vulva—rectum cancer	0.00139	0.00275	CbGeAlD
Crizotinib—YES1—smooth muscle tissue—rectum cancer	0.00137	0.00272	CbGeAlD
Crizotinib—EPHA2—mammalian vulva—rectum cancer	0.00137	0.00272	CbGeAlD
Crizotinib—SRC—epithelium—rectum cancer	0.00137	0.00271	CbGeAlD
Crizotinib—EPHA4—female reproductive system—rectum cancer	0.00137	0.00271	CbGeAlD
Crizotinib—ABL2—vagina—rectum cancer	0.00135	0.00268	CbGeAlD
Crizotinib—MAP3K2—female reproductive system—rectum cancer	0.00134	0.00266	CbGeAlD
Crizotinib—EPHB6—urethra—rectum cancer	0.00134	0.00266	CbGeAlD
Crizotinib—MAP4K5—mammalian vulva—rectum cancer	0.00134	0.00265	CbGeAlD
Crizotinib—MAP3K3—mammalian vulva—rectum cancer	0.00134	0.00265	CbGeAlD
Crizotinib—BMP2K—vagina—rectum cancer	0.00134	0.00265	CbGeAlD
Crizotinib—YES1—renal system—rectum cancer	0.00132	0.00262	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—rectum cancer	0.00132	0.00261	CbGeAlD
Crizotinib—MET—lymph node—rectum cancer	0.00132	0.00261	CbGeAlD
Crizotinib—TBK1—female reproductive system—rectum cancer	0.00132	0.0026	CbGeAlD
Crizotinib—PTK2—female reproductive system—rectum cancer	0.00132	0.0026	CbGeAlD
Crizotinib—STK10—renal system—rectum cancer	0.00131	0.00259	CbGeAlD
Crizotinib—TYK2—female reproductive system—rectum cancer	0.00131	0.00259	CbGeAlD
Crizotinib—TAOK3—renal system—rectum cancer	0.0013	0.00258	CbGeAlD
Crizotinib—YES1—urethra—rectum cancer	0.0013	0.00257	CbGeAlD
Crizotinib—PTK2B—vagina—rectum cancer	0.00129	0.00256	CbGeAlD
Crizotinib—IRAK1—female reproductive system—rectum cancer	0.00129	0.00255	CbGeAlD
Crizotinib—RIPK2—vagina—rectum cancer	0.00128	0.00254	CbGeAlD
Crizotinib—TAOK3—urethra—rectum cancer	0.00128	0.00254	CbGeAlD
Crizotinib—EPHB6—mammalian vulva—rectum cancer	0.00128	0.00253	CbGeAlD
Crizotinib—CDK7—lymph node—rectum cancer	0.00128	0.00253	CbGeAlD
Crizotinib—SRC—renal system—rectum cancer	0.00127	0.00252	CbGeAlD
Crizotinib—TAOK2—lymph node—rectum cancer	0.00127	0.00251	CbGeAlD
Crizotinib—RPS6KB1—female reproductive system—rectum cancer	0.00127	0.00251	CbGeAlD
Crizotinib—FGR—female reproductive system—rectum cancer	0.00126	0.00249	CbGeAlD
Crizotinib—AXL—female reproductive system—rectum cancer	0.00125	0.00248	CbGeAlD
Crizotinib—EPHA4—vagina—rectum cancer	0.00124	0.00245	CbGeAlD
Crizotinib—YES1—mammalian vulva—rectum cancer	0.00124	0.00245	CbGeAlD
Crizotinib—STK10—mammalian vulva—rectum cancer	0.00122	0.00242	CbGeAlD
Crizotinib—TAOK3—mammalian vulva—rectum cancer	0.00122	0.00242	CbGeAlD
Crizotinib—ACVR1B—lymph node—rectum cancer	0.00122	0.00241	CbGeAlD
Crizotinib—EPHA3—lymph node—rectum cancer	0.00122	0.00241	CbGeAlD
Crizotinib—EPHB4—female reproductive system—rectum cancer	0.0012	0.00237	CbGeAlD
Crizotinib—PTK2—vagina—rectum cancer	0.00119	0.00236	CbGeAlD
Crizotinib—TBK1—vagina—rectum cancer	0.00119	0.00236	CbGeAlD
Crizotinib—JAK2—female reproductive system—rectum cancer	0.00119	0.00235	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—rectum cancer	0.00119	0.00235	CbGeAlD
Crizotinib—TYK2—vagina—rectum cancer	0.00118	0.00234	CbGeAlD
Crizotinib—EPHA2—female reproductive system—rectum cancer	0.00117	0.00233	CbGeAlD
Crizotinib—JAK3—lymph node—rectum cancer	0.00116	0.0023	CbGeAlD
Crizotinib—DCLK1—lymph node—rectum cancer	0.00116	0.00229	CbGeAlD
Crizotinib—PLK4—lymph node—rectum cancer	0.00115	0.00227	CbGeAlD
Crizotinib—MAP4K5—female reproductive system—rectum cancer	0.00115	0.00227	CbGeAlD
Crizotinib—MAP3K3—female reproductive system—rectum cancer	0.00115	0.00227	CbGeAlD
Crizotinib—TEK—female reproductive system—rectum cancer	0.00115	0.00227	CbGeAlD
Crizotinib—RPS6KB1—vagina—rectum cancer	0.00115	0.00227	CbGeAlD
Crizotinib—STK4—lymph node—rectum cancer	0.00114	0.00226	CbGeAlD
Crizotinib—FGR—vagina—rectum cancer	0.00114	0.00225	CbGeAlD
Crizotinib—LCK—vagina—rectum cancer	0.00114	0.00225	CbGeAlD
Crizotinib—AXL—vagina—rectum cancer	0.00113	0.00224	CbGeAlD
Crizotinib—CSF1R—urethra—rectum cancer	0.00112	0.00222	CbGeAlD
Crizotinib—ABL1—seminal vesicle—rectum cancer	0.00112	0.00222	CbGeAlD
Crizotinib—SLK—vagina—rectum cancer	0.00109	0.00216	CbGeAlD
Crizotinib—EPHB4—vagina—rectum cancer	0.00108	0.00214	CbGeAlD
Crizotinib—FER—lymph node—rectum cancer	0.00108	0.00214	CbGeAlD
Crizotinib—ALK—lymph node—rectum cancer	0.00108	0.00214	CbGeAlD
Crizotinib—JAK2—vagina—rectum cancer	0.00108	0.00213	CbGeAlD
Crizotinib—TNK1—lymph node—rectum cancer	0.00107	0.00211	CbGeAlD
Crizotinib—CSF1R—mammalian vulva—rectum cancer	0.00107	0.00211	CbGeAlD
Crizotinib—EPHA2—vagina—rectum cancer	0.00106	0.0021	CbGeAlD
Crizotinib—YES1—female reproductive system—rectum cancer	0.00106	0.0021	CbGeAlD
Crizotinib—MAP4K1—lymph node—rectum cancer	0.00106	0.00209	CbGeAlD
Crizotinib—BMPR1B—lymph node—rectum cancer	0.00106	0.00209	CbGeAlD
Crizotinib—STK10—female reproductive system—rectum cancer	0.00105	0.00208	CbGeAlD
Crizotinib—TAOK3—female reproductive system—rectum cancer	0.00105	0.00207	CbGeAlD
Crizotinib—TNK2—lymph node—rectum cancer	0.00104	0.00205	CbGeAlD
Crizotinib—IGF1R—lymph node—rectum cancer	0.00104	0.00205	CbGeAlD
Crizotinib—MAP4K5—vagina—rectum cancer	0.00104	0.00205	CbGeAlD
Crizotinib—MAP3K3—vagina—rectum cancer	0.00104	0.00205	CbGeAlD
Crizotinib—MAP4K2—lymph node—rectum cancer	0.00102	0.00202	CbGeAlD
Crizotinib—SRC—female reproductive system—rectum cancer	0.00102	0.00202	CbGeAlD
Crizotinib—STK3—lymph node—rectum cancer	0.00101	0.002	CbGeAlD
Crizotinib—TIE1—lymph node—rectum cancer	0.00101	0.002	CbGeAlD
Crizotinib—EPHB6—vagina—rectum cancer	0.000991	0.00196	CbGeAlD
Crizotinib—AURKA—lymph node—rectum cancer	0.000983	0.00195	CbGeAlD
Crizotinib—TESK1—lymph node—rectum cancer	0.000975	0.00193	CbGeAlD
Crizotinib—YES1—vagina—rectum cancer	0.000957	0.0019	CbGeAlD
Crizotinib—STK10—vagina—rectum cancer	0.000949	0.00188	CbGeAlD
Crizotinib—MERTK—lymph node—rectum cancer	0.000949	0.00188	CbGeAlD
Crizotinib—TAOK3—vagina—rectum cancer	0.000945	0.00187	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—rectum cancer	0.000937	0.00186	CbGeAlD
Crizotinib—LIMK2—lymph node—rectum cancer	0.000928	0.00184	CbGeAlD
Crizotinib—NUAK2—lymph node—rectum cancer	0.000925	0.00183	CbGeAlD
Crizotinib—ACVR1—lymph node—rectum cancer	0.000918	0.00182	CbGeAlD
Crizotinib—FLT3—lymph node—rectum cancer	0.000918	0.00182	CbGeAlD
Crizotinib—MAP3K12—lymph node—rectum cancer	0.000918	0.00182	CbGeAlD
Crizotinib—CSF1R—female reproductive system—rectum cancer	0.000914	0.00181	CbGeAlD
Crizotinib—ABL1—renal system—rectum cancer	0.000902	0.00179	CbGeAlD
Crizotinib—STK35—lymph node—rectum cancer	0.000899	0.00178	CbGeAlD
Crizotinib—ABL1—urethra—rectum cancer	0.000886	0.00175	CbGeAlD
Crizotinib—ABL2—lymph node—rectum cancer	0.000876	0.00173	CbGeAlD
Crizotinib—BMP2K—lymph node—rectum cancer	0.000866	0.00171	CbGeAlD
Crizotinib—ABL1—mammalian vulva—rectum cancer	0.000844	0.00167	CbGeAlD
Crizotinib—PTK2B—lymph node—rectum cancer	0.000836	0.00165	CbGeAlD
Crizotinib—RIPK2—lymph node—rectum cancer	0.000829	0.00164	CbGeAlD
Crizotinib—CSF1R—vagina—rectum cancer	0.000827	0.00164	CbGeAlD
Crizotinib—EPHA4—lymph node—rectum cancer	0.000802	0.00159	CbGeAlD
Crizotinib—MAP3K2—lymph node—rectum cancer	0.000786	0.00156	CbGeAlD
Crizotinib—PTK2—lymph node—rectum cancer	0.00077	0.00152	CbGeAlD
Crizotinib—TBK1—lymph node—rectum cancer	0.00077	0.00152	CbGeAlD
Crizotinib—TYK2—lymph node—rectum cancer	0.000765	0.00151	CbGeAlD
Crizotinib—IRAK1—lymph node—rectum cancer	0.000755	0.00149	CbGeAlD
Crizotinib—RPS6KB1—lymph node—rectum cancer	0.000741	0.00147	CbGeAlD
Crizotinib—LCK—lymph node—rectum cancer	0.000736	0.00146	CbGeAlD
Crizotinib—FGR—lymph node—rectum cancer	0.000736	0.00146	CbGeAlD
Crizotinib—AXL—lymph node—rectum cancer	0.000733	0.00145	CbGeAlD
Crizotinib—ABL1—female reproductive system—rectum cancer	0.000723	0.00143	CbGeAlD
Crizotinib—SLK—lymph node—rectum cancer	0.000706	0.0014	CbGeAlD
Crizotinib—EPHB4—lymph node—rectum cancer	0.000701	0.00139	CbGeAlD
Crizotinib—JAK2—lymph node—rectum cancer	0.000696	0.00138	CbGeAlD
Crizotinib—EPHA2—lymph node—rectum cancer	0.000687	0.00136	CbGeAlD
Crizotinib—TEK—lymph node—rectum cancer	0.000671	0.00133	CbGeAlD
Crizotinib—MAP3K3—lymph node—rectum cancer	0.000671	0.00133	CbGeAlD
Crizotinib—MAP4K5—lymph node—rectum cancer	0.000671	0.00133	CbGeAlD
Crizotinib—ABL1—vagina—rectum cancer	0.000654	0.00129	CbGeAlD
Crizotinib—EPHB6—lymph node—rectum cancer	0.000641	0.00127	CbGeAlD
Crizotinib—YES1—lymph node—rectum cancer	0.000619	0.00123	CbGeAlD
Crizotinib—STK10—lymph node—rectum cancer	0.000614	0.00121	CbGeAlD
Crizotinib—TAOK3—lymph node—rectum cancer	0.000611	0.00121	CbGeAlD
Crizotinib—SRC—lymph node—rectum cancer	0.000596	0.00118	CbGeAlD
Crizotinib—CSF1R—lymph node—rectum cancer	0.000535	0.00106	CbGeAlD
Crizotinib—CYP3A5—renal system—rectum cancer	0.000528	0.00105	CbGeAlD
Crizotinib—ABL1—lymph node—rectum cancer	0.000423	0.000837	CbGeAlD
Crizotinib—CYP3A4—renal system—rectum cancer	0.000396	0.000785	CbGeAlD
Crizotinib—CYP3A5—vagina—rectum cancer	0.000383	0.000757	CbGeAlD
Crizotinib—ABCB1—seminal vesicle—rectum cancer	0.000348	0.000689	CbGeAlD
Crizotinib—CYP3A4—female reproductive system—rectum cancer	0.000317	0.000628	CbGeAlD
Crizotinib—ABCB1—epithelium—rectum cancer	0.000303	0.000599	CbGeAlD
Crizotinib—ABCB1—renal system—rectum cancer	0.000281	0.000555	CbGeAlD
Crizotinib—ABCB1—urethra—rectum cancer	0.000276	0.000546	CbGeAlD
Crizotinib—ABCB1—mammalian vulva—rectum cancer	0.000262	0.000519	CbGeAlD
Crizotinib—ABCB1—female reproductive system—rectum cancer	0.000225	0.000445	CbGeAlD
Crizotinib—ABCB1—vagina—rectum cancer	0.000203	0.000402	CbGeAlD
Crizotinib—ABCB1—lymph node—rectum cancer	0.000131	0.00026	CbGeAlD
Crizotinib—FER—Signaling Pathways—KRAS—rectum cancer	5.6e-05	0.000113	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—HRAS—rectum cancer	5.58e-05	0.000113	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—KRAS—rectum cancer	5.54e-05	0.000112	CbGpPWpGaD
Crizotinib—TBK1—Immune System—NRAS—rectum cancer	5.51e-05	0.000111	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—NRAS—rectum cancer	5.46e-05	0.00011	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—KRAS—rectum cancer	5.45e-05	0.00011	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—NRAS—rectum cancer	5.44e-05	0.00011	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—HRAS—rectum cancer	5.43e-05	0.00011	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—HRAS—rectum cancer	5.4e-05	0.000109	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—HRAS—rectum cancer	5.38e-05	0.000109	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—HRAS—rectum cancer	5.36e-05	0.000108	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—HRAS—rectum cancer	5.35e-05	0.000108	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	5.33e-05	0.000108	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—KRAS—rectum cancer	5.31e-05	0.000107	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—KRAS—rectum cancer	5.3e-05	0.000107	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—NRAS—rectum cancer	5.29e-05	0.000107	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—HRAS—rectum cancer	5.29e-05	0.000107	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—HRAS—rectum cancer	5.16e-05	0.000104	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—KRAS—rectum cancer	5.15e-05	0.000104	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—HRAS—rectum cancer	5.11e-05	0.000103	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—TP53—rectum cancer	5.09e-05	0.000103	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—HRAS—rectum cancer	5.09e-05	0.000103	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—KRAS—rectum cancer	5.08e-05	0.000103	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—NRAS—rectum cancer	5.07e-05	0.000102	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—TP53—rectum cancer	5.02e-05	0.000101	CbGpPWpGaD
Crizotinib—JAK3—Immune System—NRAS—rectum cancer	4.99e-05	0.000101	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—NRAS—rectum cancer	4.99e-05	0.000101	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—TP53—rectum cancer	4.98e-05	0.000101	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—TP53—rectum cancer	4.98e-05	0.000101	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—NRAS—rectum cancer	4.96e-05	0.0001	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—HRAS—rectum cancer	4.96e-05	0.0001	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—HRAS—rectum cancer	4.94e-05	9.98e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—HRAS—rectum cancer	4.94e-05	9.98e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—NRAS—rectum cancer	4.93e-05	9.97e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—HRAS—rectum cancer	4.89e-05	9.89e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—NRAS—rectum cancer	4.89e-05	9.89e-05	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—KRAS—rectum cancer	4.88e-05	9.86e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—NRAS—rectum cancer	4.87e-05	9.84e-05	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—HRAS—rectum cancer	4.87e-05	9.83e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—KRAS—rectum cancer	4.86e-05	9.81e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—KRAS—rectum cancer	4.82e-05	9.74e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—KRAS—rectum cancer	4.82e-05	9.74e-05	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—HRAS—rectum cancer	4.8e-05	9.7e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—HRAS—rectum cancer	4.78e-05	9.67e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—HRAS—rectum cancer	4.76e-05	9.62e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—HRAS—rectum cancer	4.76e-05	9.62e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—KRAS—rectum cancer	4.75e-05	9.59e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—TP53—rectum cancer	4.72e-05	9.54e-05	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—HRAS—rectum cancer	4.71e-05	9.52e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—KRAS—rectum cancer	4.7e-05	9.49e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—KRAS—rectum cancer	4.68e-05	9.46e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—NRAS—rectum cancer	4.67e-05	9.43e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—HRAS—rectum cancer	4.63e-05	9.36e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—NRAS—rectum cancer	4.58e-05	9.25e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—KRAS—rectum cancer	4.55e-05	9.2e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—HRAS—rectum cancer	4.51e-05	9.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—HRAS—rectum cancer	4.5e-05	9.1e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—NRAS—rectum cancer	4.46e-05	9.01e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—NRAS—rectum cancer	4.44e-05	8.98e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—NRAS—rectum cancer	4.4e-05	8.9e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—NRAS—rectum cancer	4.38e-05	8.86e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—HRAS—rectum cancer	4.38e-05	8.85e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—NRAS—rectum cancer	4.38e-05	8.85e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—NRAS—rectum cancer	4.36e-05	8.82e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—KRAS—rectum cancer	4.36e-05	8.82e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—HRAS—rectum cancer	4.32e-05	8.73e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—TP53—rectum cancer	4.32e-05	8.72e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—NRAS—rectum cancer	4.3e-05	8.69e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—KRAS—rectum cancer	4.29e-05	8.67e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—KRAS—rectum cancer	4.29e-05	8.67e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—NRAS—rectum cancer	4.28e-05	8.64e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—KRAS—rectum cancer	4.27e-05	8.63e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—NRAS—rectum cancer	4.26e-05	8.61e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—KRAS—rectum cancer	4.24e-05	8.58e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—NRAS—rectum cancer	4.23e-05	8.55e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—KRAS—rectum cancer	4.21e-05	8.51e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—KRAS—rectum cancer	4.19e-05	8.47e-05	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—HRAS—rectum cancer	4.15e-05	8.38e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—HRAS—rectum cancer	4.13e-05	8.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—NRAS—rectum cancer	4.12e-05	8.33e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—HRAS—rectum cancer	4.1e-05	8.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—HRAS—rectum cancer	4.1e-05	8.28e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—HRAS—rectum cancer	4.03e-05	8.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—KRAS—rectum cancer	4.02e-05	8.12e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NRAS—rectum cancer	4.01e-05	8.1e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—HRAS—rectum cancer	3.99e-05	8.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—HRAS—rectum cancer	3.98e-05	8.04e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	3.94e-05	7.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—KRAS—rectum cancer	3.94e-05	7.96e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—HRAS—rectum cancer	3.87e-05	7.82e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KRAS—rectum cancer	3.84e-05	7.76e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—KRAS—rectum cancer	3.83e-05	7.73e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KRAS—rectum cancer	3.79e-05	7.66e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KRAS—rectum cancer	3.77e-05	7.62e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—rectum cancer	3.77e-05	7.62e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KRAS—rectum cancer	3.77e-05	7.62e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KRAS—rectum cancer	3.76e-05	7.59e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—rectum cancer	3.74e-05	7.56e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—rectum cancer	3.72e-05	7.53e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—HRAS—rectum cancer	3.71e-05	7.5e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—KRAS—rectum cancer	3.7e-05	7.48e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—KRAS—rectum cancer	3.68e-05	7.44e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—KRAS—rectum cancer	3.67e-05	7.41e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—HRAS—rectum cancer	3.65e-05	7.37e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—HRAS—rectum cancer	3.65e-05	7.37e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KRAS—rectum cancer	3.64e-05	7.36e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—HRAS—rectum cancer	3.63e-05	7.34e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—NRAS—rectum cancer	3.62e-05	7.31e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—NRAS—rectum cancer	3.61e-05	7.29e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HRAS—rectum cancer	3.61e-05	7.29e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—HRAS—rectum cancer	3.58e-05	7.23e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—HRAS—rectum cancer	3.56e-05	7.2e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NRAS—rectum cancer	3.55e-05	7.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KRAS—rectum cancer	3.55e-05	7.17e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	3.5e-05	7.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—rectum cancer	3.5e-05	7.08e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—NRAS—rectum cancer	3.49e-05	7.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—NRAS—rectum cancer	3.47e-05	7.01e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NRAS—rectum cancer	3.47e-05	7e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—KRAS—rectum cancer	3.45e-05	6.97e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—NRAS—rectum cancer	3.44e-05	6.95e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—HRAS—rectum cancer	3.41e-05	6.9e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—rectum cancer	3.41e-05	6.89e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—HRAS—rectum cancer	3.35e-05	6.77e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—rectum cancer	3.34e-05	6.75e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—rectum cancer	3.26e-05	6.59e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NRAS—rectum cancer	3.26e-05	6.59e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—rectum cancer	3.25e-05	6.57e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NRAS—rectum cancer	3.22e-05	6.52e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—rectum cancer	3.22e-05	6.51e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—rectum cancer	3.21e-05	6.48e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—rectum cancer	3.2e-05	6.48e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—rectum cancer	3.2e-05	6.46e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—rectum cancer	3.19e-05	6.45e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—rectum cancer	3.17e-05	6.4e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—rectum cancer	3.15e-05	6.36e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—rectum cancer	3.13e-05	6.32e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—rectum cancer	3.12e-05	6.3e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KRAS—rectum cancer	3.11e-05	6.29e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KRAS—rectum cancer	3.11e-05	6.28e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—rectum cancer	3.09e-05	6.25e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—rectum cancer	3.07e-05	6.2e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—rectum cancer	3.07e-05	6.2e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—KRAS—rectum cancer	3.05e-05	6.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—rectum cancer	3.01e-05	6.09e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KRAS—rectum cancer	3e-05	6.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—KRAS—rectum cancer	2.98e-05	6.03e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KRAS—rectum cancer	2.98e-05	6.03e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—rectum cancer	2.96e-05	5.98e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—rectum cancer	2.93e-05	5.93e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—rectum cancer	2.92e-05	5.91e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—rectum cancer	2.87e-05	5.81e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—rectum cancer	2.83e-05	5.72e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—rectum cancer	2.81e-05	5.67e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—rectum cancer	2.77e-05	5.61e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—rectum cancer	2.75e-05	5.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—rectum cancer	2.73e-05	5.51e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—rectum cancer	2.71e-05	5.49e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—rectum cancer	2.71e-05	5.48e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—rectum cancer	2.65e-05	5.35e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—rectum cancer	2.64e-05	5.34e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—rectum cancer	2.64e-05	5.34e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—rectum cancer	2.63e-05	5.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—rectum cancer	2.63e-05	5.31e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TYMS—rectum cancer	2.6e-05	5.26e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—rectum cancer	2.6e-05	5.25e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—rectum cancer	2.56e-05	5.18e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—rectum cancer	2.55e-05	5.16e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—rectum cancer	2.55e-05	5.16e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—rectum cancer	2.54e-05	5.12e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—rectum cancer	2.54e-05	5.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—rectum cancer	2.52e-05	5.09e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—rectum cancer	2.52e-05	5.09e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—rectum cancer	2.47e-05	5e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—rectum cancer	2.47e-05	4.98e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—rectum cancer	2.44e-05	4.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—rectum cancer	2.4e-05	4.85e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—rectum cancer	2.39e-05	4.82e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—rectum cancer	2.36e-05	4.77e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—rectum cancer	2.34e-05	4.72e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—rectum cancer	2.33e-05	4.71e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—rectum cancer	2.32e-05	4.68e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—rectum cancer	2.26e-05	4.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—rectum cancer	2.26e-05	4.57e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—rectum cancer	2.25e-05	4.56e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—rectum cancer	2.24e-05	4.54e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—rectum cancer	2.22e-05	4.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—rectum cancer	2.22e-05	4.48e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—rectum cancer	2.21e-05	4.46e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—rectum cancer	2.2e-05	4.44e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—rectum cancer	2.2e-05	4.44e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—rectum cancer	2.17e-05	4.38e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—rectum cancer	2.14e-05	4.32e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—rectum cancer	2.11e-05	4.26e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—rectum cancer	2.1e-05	4.25e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—rectum cancer	2.1e-05	4.25e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—rectum cancer	2.07e-05	4.19e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—rectum cancer	2.07e-05	4.19e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—rectum cancer	2.07e-05	4.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—rectum cancer	2.05e-05	4.14e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—rectum cancer	2.01e-05	4.06e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—rectum cancer	1.98e-05	4.01e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—rectum cancer	1.96e-05	3.97e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—rectum cancer	1.94e-05	3.92e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—rectum cancer	1.94e-05	3.92e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—rectum cancer	1.92e-05	3.89e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—rectum cancer	1.92e-05	3.88e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—rectum cancer	1.91e-05	3.87e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—rectum cancer	1.91e-05	3.85e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—rectum cancer	1.88e-05	3.79e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—rectum cancer	1.87e-05	3.77e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—rectum cancer	1.86e-05	3.76e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—rectum cancer	1.82e-05	3.67e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—rectum cancer	1.81e-05	3.66e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—rectum cancer	1.76e-05	3.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—rectum cancer	1.76e-05	3.55e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—rectum cancer	1.72e-05	3.49e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—rectum cancer	1.72e-05	3.47e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—rectum cancer	1.7e-05	3.44e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—rectum cancer	1.67e-05	3.38e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—rectum cancer	1.66e-05	3.35e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—rectum cancer	1.65e-05	3.33e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—rectum cancer	1.63e-05	3.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—rectum cancer	1.62e-05	3.28e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—rectum cancer	1.61e-05	3.26e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—rectum cancer	1.6e-05	3.24e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—rectum cancer	1.57e-05	3.17e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—rectum cancer	1.55e-05	3.14e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—rectum cancer	1.54e-05	3.12e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—rectum cancer	1.54e-05	3.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—rectum cancer	1.5e-05	3.03e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—rectum cancer	1.48e-05	2.99e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—rectum cancer	1.43e-05	2.88e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—rectum cancer	1.42e-05	2.87e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—rectum cancer	1.36e-05	2.75e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—rectum cancer	1.36e-05	2.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—rectum cancer	1.34e-05	2.7e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—rectum cancer	1.27e-05	2.56e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—rectum cancer	1.26e-05	2.54e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—rectum cancer	1.21e-05	2.45e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—rectum cancer	1.21e-05	2.44e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—rectum cancer	1.2e-05	2.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—rectum cancer	1.19e-05	2.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—rectum cancer	1.17e-05	2.36e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—rectum cancer	1.14e-05	2.29e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—rectum cancer	1.04e-05	2.1e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—rectum cancer	1.04e-05	2.09e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—rectum cancer	9.94e-06	2.01e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—rectum cancer	9.2e-06	1.86e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—rectum cancer	8.8e-06	1.78e-05	CbGpPWpGaD
